Sage Therapeutics, Inc. (NASDAQ:SAGE) – Research analysts at William Blair cut their FY2018 earnings estimates for shares of Sage Therapeutics in a note issued to investors on Tuesday. William Blair analyst T. Lugo now anticipates that the biopharmaceutical company will post earnings of ($6.70) per share for the year, down from their previous estimate of ($6.03). William Blair also issued estimates for Sage Therapeutics’ FY2019 earnings at ($5.15) EPS.

Several other analysts also recently weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of Sage Therapeutics in a report on Thursday. They issued an “outperform” rating and a $117.00 target price for the company. BMO Capital Markets lifted their target price on shares of Sage Therapeutics from $80.00 to $84.00 and gave the company an “outperform” rating in a report on Thursday. Chardan Capital reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday. Needham & Company LLC dropped their target price on shares of Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $91.00 target price (down previously from $104.00) on shares of Sage Therapeutics in a report on Wednesday. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Sage Therapeutics has an average rating of “Buy” and an average target price of $86.77.

ILLEGAL ACTIVITY WARNING: “Sage Therapeutics, Inc. (SAGE) Forecasted to Post FY2018 Earnings of ($6.70) Per Share” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/16/sage-therapeutics-inc-sage-forecasted-to-post-fy2018-earnings-of-6-70-per-share.html.

Shares of Sage Therapeutics (NASDAQ:SAGE) opened at 62.36 on Thursday. The firm’s 50-day moving average price is $81.33 and its 200 day moving average price is $74.82. The company’s market capitalization is $2.33 billion. Sage Therapeutics has a 52 week low of $38.30 and a 52 week high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same period in the prior year, the company earned ($1.08) earnings per share.

Large investors have recently bought and sold shares of the business. State of Wisconsin Investment Board acquired a new position in shares of Sage Therapeutics in the second quarter worth $1,991,000. Teacher Retirement System of Texas acquired a new position in shares of Sage Therapeutics in the second quarter worth $202,000. Schwab Charles Investment Management Inc. grew its stake in shares of Sage Therapeutics by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 131,440 shares of the biopharmaceutical company’s stock worth $9,342,000 after acquiring an additional 1,593 shares in the last quarter. Spark Investment Management LLC acquired a new position in shares of Sage Therapeutics in the first quarter worth $4,086,000. Finally, Rhumbline Advisers grew its stake in shares of Sage Therapeutics by 9.4% in the second quarter. Rhumbline Advisers now owns 41,138 shares of the biopharmaceutical company’s stock worth $3,276,000 after acquiring an additional 3,551 shares in the last quarter.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.